GSK delays filing, trial and abandons drug program

GlaxoSmithKline announced a significant increase in its quarterly earnings, but disappointed investors with a string of announcements about a delayed regulatory application and discontinued or delayed development programs. GSK's timeline for its closely-watched cervical cancer vaccine Cervarix has changed, with the company planning to delay filing for U.S. approval until April 2007. GSK had been aiming to file by the end of this year. GSK has also abandoned a development program for a compound to treat severe infections and put clinical trials for its diabetes drug Redono on hold. It all added up to a bleak headline for investors, who sent GSK shares down on the news.

- read the report on GSK from The Toronto Star

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.